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Purpose: Cone-beam CT (CBCT) projection images provide anatomical data in real-time over several
respiratory cycles, forming a comprehensive picture of tumor movement. We developed and validated a
method which uses these projections to determine the trajectory of and dose to highly mobile tumors during
each fraction of treatment.
Methods: CBCT images of a respiration phantom were acquired, the trajectory of which mimicked a
lung tumor with high amplitude (up to 2.5 cm) and hysteresis. A template-matching algorithm was used
to identify the location of a steel BB in each CBCT projection, and a Gaussian probability density function
for the absolute BB position was calculated which best fit the observed trajectory of the BB in the imager
geometry. Two modifications of the trajectory reconstruction were investigated: first, using respiratory phase
information to refine the trajectory estimation (Phase), and second, using the Monte Carlo (MC) method to
sample the estimated Gaussian tumor position distribution. The accuracies of the proposed methods were
evaluated by comparing the known and calculated BB trajectories in phantom-simulated clinical scenarios
using abdominal tumor volumes.
Results: With all methods, the mean position of the BB was determined with accuracy better than 0.1
mm, and root-mean-square (RMS) trajectory errors averaged 3.8±1.1% of the marker amplitude. Dosimetric
calculations using Phase methods were more accurate, with mean absolute error less than 0.5%, and with
error less than 1% in the highest-noise trajectory. MC-based trajectories prevent the over-estimation of dose,
but when viewed in an absolute sense, add a small amount of dosimetric error (<0.1%).
Conclusions: Marker trajectory and target dose-of-the-day were accurately calculated using CBCT pro-
jections. This technique provides a method to evaluate highly-mobile tumors using ordinary CBCT data, and
could facilitate better strategies to mitigate or compensate for motion during SBRT.
This manuscript was submitted to Medical Physics
I. INTRODUCTION
As radiotherapy becomes more conformal, the nega-
tive effects of tumor motion become more pronounced1.
Highly targeted techniques, such as Stereotactic Body
Radiotherapy (SBRT), rely on the establishment of a
very steep dose gradient around the tumor in order to
reduce normal tissue effects2. Motion blurs the bound-
ary between tumor and normal tissue, making this dose
gradient harder to establish. Interfraction motion can
largely be addressed by image-guided therapy techniques
such as cone-beam CT (CBCT)3; however, intrafraction
motion presents a more complicated problem. Specifi-
cally, motion makes it more difficult to ensure that the
target receives the full prescribed dose, and also adds un-
certainty when calculating the dose-of-the-day based on
pre-treatment imaging.
A common approach to account for regular intrafrac-
tion motion is to use 4-Dimensional CT (4DCT) imaging
to characterize the full range of tumor motion, and to
treat a target volume which encompasses this range4,5.
This guarantees full coverage of the tumor but increases
dose to normal tissue in the tumor vicinity. Another ap-
proach is to monitor the tumor position (either directly or
a)Author to whom correspondence should be addressed:
bernard.jones@ucdenver.edu
using surrogates), and to treat only when the tumor lies
within some specified region (i.e. gating)6,7. More recent
advances involve modifying or re-directing the treatment
beam in real-time in order to compensate for intrafrac-
tion motion8,9.
More accurate methods to account for tumor motion
are based on knowing the instantaneous tumor location
over time (i.e. the tumor trajectory). Several meth-
ods exist to determine this. If the tumor is implanted
with radiopaque fiducial markers, the position can be tri-
angulated using stereoscopic imaging from two or more
view angles10-13. Similarly, the tumor can be implanted
with electromagnetic transponders7,14, or can be moni-
tored in the treatment suite using MRI images15. One
major drawback of these methods is that they rely on
technologies or treatments not commonly available to the
majority of radiotherapy centers, or are only available for
use in certain tumor sites.
CBCT is a widely used pre-treatment imaging modal-
ity which captures a relatively low-quality 3D image of
the patient anatomy in the treatment position3. Typi-
cal clinical CBCT systems capture roughly 650 projec-
tion images, which are used to reconstruct the 3D image.
These projections are typically acquired over a 30-120
second timescale, and the reconstructed images exhibit
significant blurring due to respiratory motion. However,
the projection images themselves provide a comprehen-
sive picture of the anatomical movement, as they typ-
ically observe the motion of several respiratory cycles.
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2For tumors implanted with fiducial markers, these pro-
jections can reveal the motion of the target volume dur-
ing treatment. Unfortunately, the clinical utility of these
projections is often limited as these data are incomplete
with respect to the tumor position, since the process of
projection condenses the location of an object in 3D space
(x,y,z) to only two dimensions (u,v) in the imager ge-
ometry. Calculation of the tumor trajectory from these
projections would allow for determination of tumor mo-
tion and dose-of-the-day estimation for tumors implanted
with fiducial markers, which is often the case for tumors
of the lung, liver, or pancreas16-18. Additionally, this
information could be used in the context of Adaptive
Radiotherapy19-21.
The goal of this work was to calculate the tumor tra-
jectory using CBCT projections, and to validate the ac-
curacy of this trajectory in calculating the tumor dose.
Mathematically, determining the instantaneous 3D po-
sition of the tumor using the 2D projections acquired
during CBCT is an under-defined problem; in each pro-
jection we have two measured data points (u,v position
within the imager geometry) yet wish to calculate three
quantities (x,y,z position of the tumor). The projection
measurement confines the position to lie along a line be-
tween the imaging source and the point of detection, but
cannot by itself determine the depth of the position along
this line. Methods have been developed to estimate the
tumor position using orbiting CBCT projections, mostly
in the context of tracking/targeting mobile tumors in
real-time22-24. These methods choose the tumor location
by maximizing the expectation value of tumor position
(which maximizes the probability of hitting the tumor).
However, this may not be appropriate for dosimetric eval-
uation, since the most likely tumor location is generally
in the center of the planning target volume (PTV) and
may lead to an over-estimation of the tumor dose. More-
over, tumors which undergo large respiratory motion of-
ten exhibit a cyclical trajectory. Previous methods are
built around the assumption that tumor position is dis-
tributed randomly about the daily mean location, leading
to a Gaussian distribution of random position errors25.
However, this assumption is broken in the presence of
non-random respiratory motion, and a Gaussian distri-
bution of these positions will contain relatively large un-
certainty. For cyclical motion, the true uncertainty is
much smaller, since there is a large correlation between
position and respiratory phase.
In this work, we extended these methods for more ac-
curate calculation of tumor dosimetry in highly-mobile
tumors by incorporating information regarding the res-
piratory phase. Using a motion phantom, we validated
the accuracy of these methods, and quantified the uncer-
tainty in using CBCT projections to calculate dose-of-
the-day in mobile tumors.
II. METHODS
To quantify the motion of the target, the location of a
marker in 3D phantom geometry is calculated by exam-
ining the position of that marker in a series of orbiting
2D projection images. Our method builds on the work of
Poulsen et al 22 and proceeds as follows. First, we acquire
CBCT projections of a phantom in which the position of
a small fiducial marker is visible. Next, the position of
the fiducial marker in these projections is determined au-
tomatically using a template-matching algorithm. Then,
the acquired images are binned into different phases of
the respiratory cycle. An estimate of the likely distri-
bution of marker positions in each phase is built using
a Gaussian approximation of uncertainty22,25. Finally,
this Gaussian distribution is used to estimate the unre-
solved component of position, either by calculating the
most likely position or by using Monte Carlo methods to
sample this distribution.
A. Definition of geometry
Let (x,y,z) represent an orthogonal basis in 3D space,
with the origin corresponding to the treatment and imag-
ing isocenter. In this work, we consider the patient to
lie in the head-first supine position, and choose (x,y,z) to
correspond to the anterior-posterior (AP) or vertical, left-
right (LR) or lateral, and superior-inferior (SI) or longi-
tudinal directions, respectively. The kV source/imager is
oriented orthogonal to the z -axis, and orbits the patient
in the x/y plane (rotation about the z -axis). θ represents
the angle of the kV imaging source with respect to the x
axis. Let (u,v) describe the axes of the 2D projection im-
age, where u is parallel to the x/y plane and v is parallel
to the z -axis. Note that this coordinate system matches
those typically described in the radiotherapy literature
(e.g. the seminal work of Feldkamp et al 26); however,
particular choice of the relative directions of x, y, z, u, v,
and θ may alter the relationship and/or sign dependence
of these quantities.
B. Projection operator
Let P define the projection of a position (x,y,z) into the
(u,v) plane at an angle θ; in other words, P represents
the acquisition of a CBCT projection. SDD is the source-
to-detector distance, p is the image pixel size, SAD is
the source-to-axis distance, and ou, ov are the projected
locations of the rotational isocenter in the u,v coordinates
(the so-called piercing-point or principal point). In Eqs
1-3, u and v are given in units of pixels in imaging space.
(u, v) = P (x, y, z, θ) (1)
3u =
SDD
p
x sin(θ) + y cos(θ)
SAD − [x cos(θ)− y sin(θ)] + ou (2)
v =
SDD
p
z
SAD − [x cos(θ)− y sin(θ)] + ov (3)
Consider the following clinical scenario. A patient is
implanted with several radiopaque fiducial markers in or-
der to assist in the delineation and localization of this
tumor for treatment. A CBCT is acquired in order to vi-
sualize the patient anatomy on the day of treatment, and
involves the acquisition of several hundred images which
contain the projection of that anatomy into 2D. The ac-
quisition of this CBCT scan is represented by performing
P(θ) for values of θ from 0◦ to 360◦, and for each fidu-
cial marker, each image contains a measurement of the
marker position uθ and vθ.
C. Marker position
We used the formalism of Poulsen et al 22 to construct a
3D Gaussian probability density function (PDF) describ-
ing the marker position. A full derivation of this Gaus-
sian formalism is given in Ref 22, and for convenience of
the reader, we use the same notation when possible. This
method uses maximum-likelihood optimization to calcu-
late a PDF which best describes the observed motion of
a marker in projection images. Then, using this PDF,
the unresolved component of marker position is deter-
mined by computing the expectation value of this PDF
along the line between the x-ray source and the detection
point within the image (Fig 1).
A 3D Gaussian PDF is defined by 9 quantities: mean
location ~(r0) = (x0, y0, z0), variance (σx, σy, σz), and co-
variance (σxy, σyz, σzx). The variance and covariance to-
gether form the covariance matrix A. From this, the 3D
PDF for marker position ~(r) = (x0, y0, z0) was given by:
G(x, y, z) =
√
detB
(2pi)3
e−(~r−~r0)
TB(~r−~r0)/2 (4)
Here, B denotes the inverse covariance matrix B =
A
−1
, and T denotes the transpose operator. The func-
tional form of Eq. 4 along the line from the imaging
source to detection point (defined here as g) was de-
scribed by the following:
σ =
√
eˆTBeˆ (5)
µ =
(~r0 − ~p)TBeˆ
eˆTBeˆ
(6)
K =
√
detB
(2pi)3
e−(~p+eˆµ−~r0)
TB(~p+eˆµ−~r0)/2 (7)
g(t) = Ke−(t−mu)
2/(2σ)2 (8)
Here, eˆ describes a unit vector pointing from the ob-
served marker position to the imaging source, and ~p de-
scribes the point on the imager at which the marker was
detected (converted to patient geometry).
Using the observed marker positions (ui, vi) in each im-
age i, optimization was performed to estimate the mean
position and covariance matrix which describes the prob-
abilistic marker positions. By integrating Eq. 8, it can
be shown that the probability of finding the marker at
a given detector position is linearly proportional to the
product K · σ. The optimization finds a mean position
and covariance matrix which maximizes the total prob-
ability of finding the markers in positions observed in
each image i. The optimization was performed using the
Nelder-Mead simplex search method27.
[~r0, B] = arg min
~r0,B
∑
i
− log(Kiσi) (9)
D. Respiratory phase
Respiratory phase was determined using the SI dis-
placement of the fiducial markers. The SI position is
well-determined in the CBCT projections for locations
near the rotational isocenter, since the only error derives
from magnification effects related to (x, y) errors (Eq. 3),
which are typically on the order of 1% or less. This in-
ternal surrogate information precluded the need to define
respiratory phase based on some other surrogate, such as
chest markers or diaphragm movement.
First, the marker trajectory in the v direction was
smoothed using a five-sample moving average, and dis-
crete velocity was calculated by taking the difference be-
tween smoothed positions in sequential projections. It
is assumed that these marker positions represent tumor
trajectory in a head-first supine orientation, with the +v
axis pointing in the superior direction. End-exhale (vee)
was identified from projections where the marker velocity
switched from positive to negative; likewise, end-inhale
(vei) was identified where velocity went from negative to
positive.
Projections were binned into one of 10 respiratory
phases based on the velocity and location of the marker
relative to the end-exhale and end-inhale positions.
Phases 1-5 (inhale) consisted of projections with nega-
tive velocity, grouped into uniformly spaced bins between
subsequent vee and vei coordinates. Phases 6-10 (exhale)
consisted of projections with positive velocity, grouped
into linearly spaced bins between subsequent vei and vee
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FIG. 1. Determination of tumor position using 3D Gaussian probability. A) Using all 2D projections, a 3D Gaussian distribution
is found which best fits the observed marker trajectory. For each measured position (i.e. each projection image), the position is
determined by finding the expectation of this Gaussian distribution along the line between the x-ray source and the detection
point. B) In the phase-resolved method, a 3D distribution is independently calculated for each phase of the respiratory cycle.
coordinates. Projections at the beginning (or end) of the
motion trace (i.e. those that did not contain measure-
ments of the full cycle) used vei (or vee) coordinates of
the nearest full phase.
E. Position determination
Four methods were used to determine the 3D marker
trajectory from the projection images. These meth-
ods were implemented using in-house software developed
with Matlab (The Mathworks, Natick MA). In Method
1 (Base), position estimation followed the method of
Poulsen et al 22. Data from all projections was used dur-
ing optimization to calculate a 3D Gaussian distribution
which described the probability of finding the marker in
a given 3D location (Eq. 9). This equation was parame-
terized along the detection ray (the line between the ra-
diation source and the imager detection point), and the
marker position along this line was given by t = µ, where
µ equals the expectation value of the distance along this
line (Eqs. 5-8).
In Method 2 (MC), Monte Carlo methods were used
to select the marker position in 3D space in place of the
expectation value µ. First, the detection ray was dis-
cretized into 10,000 points, spaced linearly between the
source and detector. The PDF of the 1D Gaussian (Eq.
8) was integrated across the discretized ray to form a
normalized cumulative probability distribution function.
CDF (ti) =
∑i=I
i=1 g(ti)∑i=imax
i=1 g(ti)
(10)
Next, a random number ξ was uniformly chosen be-
tween 0 and 1. The position of the marker along the ray
was chosen to be the point T which satisfied CDF (T ) =
ξ, and this solution was found numerically.
To increase the accuracy of tracking for targets with
high respiratory motion, the trajectory of the marker
was calculated using a phase-resolved Gaussian approxi-
mation (Method 3, Phase). All projections were binned
into one of 10 respiratory phases, and Eq. 9 (optimiza-
tion of Gaussian distribution) was applied to data from
each phase independently. This resulted in a set of 10
phase-specific mean positions ~rp and inverse covariance
matrices Bp, or in other words, 10 distinct distributions
describing the position of the marker during each phase
of respiration (Fig 1B). In Method 4 (PhaseMC), both
the Phase and MC methods were applied simultaneously.
F. Motion phantom
In order to validate the proposed methods, a phantom
was used to simulate respiratory tumor motion (Quasar
Phantom, Modus Medical Devices, Inc.). This phantom
contains a 1-mm-diameter steel BB, the trajectory of
which is shown in Fig 2 for various superior-inferior (Sup-
Inf) amplitudes of motion. The trajectory is similar to
that of a lung tumor trajectory with high amplitude and
hysteresis11. A CBCT scan of this phantom was acquired
using the imaging capabilities of a Varian Truebeam ac-
celerator (Varian Medical Systems, Palo Alto, CA). 656
projection images were acquired using a half-fan trajec-
tory (θ = −180◦ → 180◦). The phantom was set to a
rate of 11 breaths-per-minute, with a maximum range
in the SI direction of 2.5 cm (resulting in maximum AP
and LR ranges of 1.2 and 0.6 cm, respectively). Multiple
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FIG. 2. Trajectory of Motion Phantom. The motion of the 1-mm-diameter steel BB embedded within the motion phantom
is shown relative to the isocenter of the CBCT imaging system. Trajectories are shown for amplitudes of motion in the Sup-
Inf direction ranging from 5 25 mm. For clarity, the trajectories are also shown projected onto the XY, XZ, and YZ axes.
Trajectories are shown relative to a standard head-first supine orientation (i.e. the primary axis of motion in the Sup-Inf
direction).
projection image datasets were acquired with trajectory
amplitudes ranging in 1 mm increments from 1 mm to
2.5 cm.
In each image, the location of the BB was determined
automatically using a template matching algorithm28. A
discretized 2D Gaussian kernel was used as a template
image, with width equal to the radius of the BB. In each
image, the normalized cross correlation was computed
between the projection image and the template29. The
location of the BB in the image was given by the location
where the normalized cross correlation was maximized.
In cases where the template matching algorithm failed,
the position was determined manually.
Using the positions of the BB in the projection images,
the trajectory of the BB in 3D space was calculated using
methods 1-4 (Sect 2.5). The accuracy of these methods
was calculated by comparing the calculated trajectory to
the true trajectory (shown in Fig 2). To simulate more
difficult and unpredictable clinical scenarios, additional
(simulated) trajectories were created. Gaussian noise was
added to the true marker trajectory by adding normally
distributed random values to the x, y, and z locations at
each point in time. Simulated trajectories were created
by varying the standard deviation of this noise from 0
to 1 mm in 0.1 mm increments between datasets. These
altered datasets were projected into 2D image space (Eqs.
1-3), and Methods 1-4 were used to calculate the marker
trajectory as described previously.
G. Dosimetric model
The goal of this study was to evaluate the accuracy
of dosimetric calculations based on reconstructed trajec-
tories. To that end, the dosimetry of the reconstructed
trajectories was compared to the dosimetry of the true
trajectory. To evaluate the dosimetry of the true and
reconstructed phantom motion trajectories, a phantom-
simulated clinical scenario was considered. A clinical tar-
get volume (CTV) was assumed to undergo the motion
trajectories under analysis. Treatment was prescribed
to a planning target volume (PTV), which included the
CTV plus an isotropic margin. To simplify the model,
and to exaggerate differences between different methods,
the dose within the PTV was assumed to equal the pre-
scription, with zero dose outside the PTV. The PTV (and
resulting dose distribution) was stationary over time,
while the CTV was translated within the PTV based on
either the true phantom trajectory or the reconstructed
trajectories. For each of the 656 points in the trajectory
(corresponding to the 656 projection images), the posi-
tion of the CTV relative to its center was given by the
instantaneous trajectory position relative to the mean
position. Based on this position, the dose was calculated
for each voxel in the CTV (i.e. based on the binary dose
model, or in other words assigning 1/656th of the pre-
scription dose for voxels inside the PTV, and zero for
those outside). Independent simulations were performed
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FIG. 3. Errors in calculating trajectory using orbiting views. Results were calculated with no corrections (Base), with phase
corrections (Phase), with Monte Carlo sampling (MC) and with both phase and Monte Carlo (PhaseMC). Results are shown
for phantom motion amplitudes in the SI direction ranging from 1 mm to 25 mm. A) Root-mean-squared (RMS) errors in
the trajectory reconstruction using different methods. Phase and PhaseMC methods reduce RMS errors by half. B) Relative
fraction of trajectory errors greater than 3 mm. Phase methods reduce the fraction of large errors, and Monte Carlo methods
increase the percentage of large errors slightly. C) Histogram of trajectory errors in all projections across all acquired datasets.
Phase methods demonstrate increased accuracy.
for CTV-to-PTV margins ranging from 0 mm to 15 mm,
and were deliberately set less than the amplitude of mo-
tion so as to allow for differences between the proposed
methods to become apparent. The goal of our analysis
was to quantify the accuracy of dosimetric calculations
using CBCT-based trajectory reconstruction. To that
end, our binary dose model serves as a conservative esti-
mate of the inaccuracies of this approach, as any errors in
position determination will be reflected in the idealized
nature of the target dosimetry simulation.
H. Validation metrics
We analyzed the accuracy of the proposed methods
(Base, MC, Phase, PhaseMC) by comparing these tra-
jectories to the true phantom motion trajectory. Each
CBCT projection dataset (656 images) constituted 656
measurements of the marker position in phantom geom-
etry. For each measurement, the error was given as the
magnitude of the 3D vector difference between the cal-
culated position and the true position. The root-mean-
squared trajectory error was given for each trajectory as
the square root of the mean of the squared errors for all
measurements in that trajectory. Additionally, the fre-
quency of large errors was computed by calculating the
fraction of measurements with errors exceeding 3 mm.
The accuracy of dosimetric calculations was computed
using our phantom-simulated clinical scenario. Since the
dosimetric results depend on the shape of the target, 32
abdominal/lung tumor volumes were used to evaluate the
accuracy of the proposed methods (mean volume, 25 ±
23 cm3; range 2.0 - 80 cm3). The reference dose was cal-
culated by performing this analysis using the exact tra-
jectory, and the calculated dose used the reconstructed
trajectories. The mean dose error was calculated for each
volume as the mean dose difference between calculated
dose and reference dose. The mean absolute dose er-
ror was calculated as the mean of the magnitude of these
dose differences across all voxel of the volume. Mean dose
error gives a sense of the dosimetric trends of each tra-
jectory reconstruction method, and can reveal whether
a given method underestimates or overestimates dose.
Mean absolute dose error denotes the overall accuracy of
a method in determining accurate dose in each voxel (by
preventing positive and negative errors from cancelling).
In addition to these metrics, dose-volume histograms of
each volume were computed for each method, and com-
pared to the reference.
III. RESULTS
A. Accuracy of trajectory reconstruction
The accuracy of the trajectory calculations are shown
in Fig. 3; results were calculated without respiratory
phase or Monte Carlo corrections (Base), with phase cor-
rections only (Phase), with Monte Carlo corrections only
(MC), and with both phase and Monte Carlo corrections
(PhaseMC). Trajectory amplitude ranged from 0 to 2.5
cm.
With all methods, the mean position of the marker was
determined with accuracy better than 0.1 mm. In Fig.
3a, it can be seen that the Phase and PhaseMC methods
reduced the root-mean-squared (RMS) trajectory errors
by 50% compared to the Base and MC methods, with
an average RMS error of 3.8 ± 1.1% of the trajectory
amplitude. In Fig 3b, the Phase and PhaseMC meth-
ods decreased the fraction of large errors (defined here
7M
ea
nP
D
os
eP
E
rr
or
PN4
PM
ax
F
0 5 10 15 20 25
-1
-0.5
0
0.5
1
MotionPAmplitudePNmmF
M
ea
nP
A
bs
.PD
os
eP
E
rr
or
PN4
PM
ax
F
0 5 10 15 20 25
0
0.5
1
1.5
2
Base
MC
Phase
PhaseMC
0 5 10 15
-1
-0.5
0
0.5
1
PTVPMarginPNmmF
0 5 10 15
0
0.5
1
1.5
2
0 0.2 0.4 0.6 0.8 1
-1
-0.5
0
0.5
1
TumorPPositionPNoisePNmmF
0 0.2 0.4 0.6 0.8 1
0
0.5
1
1.5
2
AF
BF
CF
DF
EF
FF
FIG. 4. Mean and mean absolute dose error in the reconstructed trajectories. Errors were calculated using 32 clinically-drawn
abdominal/lung CTVs. Motion amplitude ranged from 0 to 2.5 cm, and results were calculated with a range of isotropic margins
and for trajectories with added noise. Dosimetric calculations using phase-resolved methods were more accurate, with mean
absolute error less than 0.5% with zero margin, and with error less than 1% in the high-noise calculation. As noise increases,
expectation-based methods generate a trajectory which over-estimates the dose to the CTV. Monte Carlo-based trajectories
under-estimate dose by an average of 0.2% of prescription dose, even as trajectory noise increases. In A) and B), the noise is 0
mm and the margin is 4 mm. In C) and D), the amplitude is 2.5 mm and the noise is 0 mm. In E) and F), the amplitude is
1.2 mm and the margin is 4 mm.
as trajectory error > 3 mm) by an average of 80%. MC
methods increased both the RMS trajectory error and
percentage of large errors slightly. Fig. 3c shows his-
tograms of trajectory errors in all projections across all
acquired datasets (amplitudes ranging from 1 mm to 25
mm in 1 mm increments). Trajectory error was less than
1mm in 92% of projections (Phase and PhaseMC) and
82% of projections (Base).
B. Dosimetric Accuracy
Fig. 4 shows the distribution of mean dose errors
and mean absolute dose errors using trajectories recon-
structed with the Base, MC, Phase, and PhaseMC meth-
ods. Results are shown across variations in trajectory
amplitude, PTV margin size, and amount of added tra-
jectory noise.
Dose errors increased sharply as the motion amplitude
increased, although in the Phase and PhaseMC methods,
absolute error never exceeded 0.5% of the prescription
dose. In general, dose errors decreased as the margin size
increased, mainly due to an overall reduction in the con-
tribution of motion seen by having more margin around
the CTV. However, it can also be seen that mean dose
error was lower when using Phase and PhaseMC trajec-
tory estimation methods. This is likely due to the lower
RMS trajectory error demonstrated by these methods.
As gaussian trajectory noise increased, the expectation-
based methods Base and Phase tended to overestimate
dose, while Monte Carlo methods MC and PhaseMC
tended to underestimate it. While Monte Carlo methods
prevented the overestimation of dose, they also slightly
increased the overall absolute error (<0.1%).
Fig. 5 shows the accuracy of each method in de-
terming dosimetric parameters D90 and D95 for vary-
ing amplitudes, PTV margin sizes, and trajectory noise.
One can see that the error of Phase methods was lower
than the error in methods which ignore respiratory phase.
Expectation-based methods again overestimated the dose
(relative to the true value) and Monte-Carlo methods un-
derestimated it, but the Base and Phase methods had a
lower absolute error. The greatest accuracy was seen in
the Phase method, which was able to determine D90 and
D95 of the CTV to within 0.5% relative to prescription.
IV. DISCUSSION
In this work, we have developed and tested methods
to evaluate dose to a moving tumor using data from a
standard clinical cone-beam CT. In particular, we have
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margins and for trajectories with added noise. Phase-resolved methods increased the accuracy of these dose metric calculations.
As trajectory noise increased, the Base and Phase methods tended to overestimate D90 and D95, while MC methods prevented
overestimation of dose. In A) and B), the noise is 0 mm and the margin is 4 mm. In C) and D), the amplitude is 2.5 mm and
the noise is 0 mm. In E) and F), the amplitude is 1.2 mm and the margin is 4 mm.
tailored these methods to the problem of calculating dose
to highly mobile tumors implanted with fiducial markers,
such as lesions in the lung, pancreas, or liver16-18. The
trajectory and subsequent dose received by the target
volume was determined with minimal error. Errors in
mean position did not exceed 0.1 mm, and the RMS tra-
jectory error averaged 3.8% of the total range of motion.
Using the Phase method, the mean dose and mean ab-
solute dose were calculated with over 99% accuracy, and
D90/D95 were determined to within 0.5% of the true
value.
By incorporating information related to the respira-
tory cycle, the accuracy of tumor trajectory reconstruc-
tion and subsequent dosimetric analysis was improved.
The 3D Gaussian PDF utilized in this study stems from
the work of Papiez and Langer25, where it was assumed
that any systematic position errors are corrected with
daily image guidance, and that only random fluctuations
remain. Thus the central limit theorem dictates that the
distribution of the remaining random errors is Gaussian.
However, this assumption is broken for tumors which un-
dergo regular respiratory motion, and the distribution
of the trajectory about the mean position is no longer
well definied as Gaussian. By creating a unique Gaus-
sian distribution for each portion of the respiratory cy-
cle, this effect is minimized, and the accuracy of trajec-
tory reconstruction is improved. This method does have
limitations; it cannot be used for tumors which undergo
non-cyclical motion, such as prostate tumors. It is also
difficult to determine the respiratory phase in real-time.
Given the prevalence of CBCT, this method may pro-
vide a useful technique to clinically estimate the dose-
of-the-day received by a mobile tumor, since over half of
radiation oncology clinics perform some cone-beam CT
imaging for localization30. Our analysis is directed to-
wards tumors implanted with fiducial markers, but also
holds in cases without fiducials as long as the tumor lo-
cation can be discerned in each projection (as has been
demonstrated in lung tumors31,32). In theory, our method
allows for very accurate trajectory/dose reconstruction,
since data are obtained using a much more comprehensive
motion profile than other techniques. A CBCT projec-
tion dataset constitutes upwards of 600 samples of tu-
mor position, whereas 4D CT typically uses only 10 res-
piratory phases, and has been shown to not accurately
represent daily intrafraction motion of the abdomen33,34.
As radiotherapy becomes more conformal, and hypofrac-
tionation becomes more commonplace, it becomes crucial
to understand and account for the effects of tumor mo-
tion on dosimetry. This method could be used to design
patient-specific, optimized margins for treatment, or to
verify the adequacy of the margins used. It could also be
used to decide between motion management strategies
on a patient-specific basis (such as breath-hold, gating,
9or free-breathing). It should be said that while we have
validated the accuracy of our method in a simple clinical
scenario, true dose-of-the-day reconstruction would re-
quire a more sophisticated dosimetric approach. By con-
structing a simplified clinical scenario which maximizes
the impact of tumor motion, our results indicate that
tumor trajectories can be derived from CBCT projec-
tion datasets with sufficient accuracy to determine true
dose. An additional benefit of this method is that the
processing time is short. Template-matching to deter-
mine seed locations can be performed in real-time, and it
takes roughly 2 seconds to calculate the trajectory once
the projected fiducial locations are known. However, to
build the 3D PDF, one must know the entire set of pro-
jected locations; in other words, the PDF cannot be built
until after CBCT acquisition is completed. Our method
could be applied to generate an accurate estimate of tu-
mor dosimetry shortly after the completion of the CBCT
acquisition.
The conditions of this study were chosen to test the
boundaries of dose reconstruction in highly mobile tu-
mors. Ranging up to 2.5 cm, the amplitude of motion
in the SI direction corresponded to the displacement of
very highly mobile lower lobe lung tumors, and exceeds
the range of liver and other abdominal tumors11,35. Hys-
teresis was also exaggerated, and motion in the AP and
LR directions (up to 1.2 and 0.6 cm) exceeded that seen
in clinical cases11,35. In addition to the large range of
motion, the effects of that motion on the dose were ex-
aggerated by assuming perfect dose fall-off outside the
PTV. Our methods were also tested over a wide range
of tumor volumes, and with up to 1 mm of Gaussian
noise added to each point in the trajectory. Even un-
der these circumstances, dose metrics of the tumor were
determined accurately. One may note that the RMS tra-
jectory error reported in this work (1-2 mm) exceeds the
mean error in the similar work of Poulsen et al 36. This
can be explained by the large amplitude of motion in the
current study, and agrees well with the maximum RMS
error (> 2 mm) reported for lung tumors in that work.
Additionally, these results give insight as to the scale of
motion which causes the greatest dosimetric inaccuracy
for each method. In Fig. 4C, errors increase for the Base
and MC methods as the magin size approaches the range
of 5-8 mm, while the Phase and PhaseMC see the great-
est error for 4-5 mm margins. Since our dosimetric model
is sensitive to motion equal to or greater than the PTV
margin, and the frequency of motion errors decreases ex-
ponentially for larger errors (Fig 3C), these results sug-
gest that motion on the order of 7 mm has the grestest
effect for the Base and MC methods, and on the order of
4 mm for the Phase and PhaseMC methods.
It is clear from these results that incorporation of respi-
ratory phase information is beneficial when reconstruct-
ing the tumor trajectory of highly mobile tumors. How-
ever, the role of MC sampling is mixed. In the Base
scenario, the position of the tumor is determined as the
expectation value of the Gaussian PDF along the detec-
tion ray. Yet one expects this determination to exhibit
a Gaussian error profile, as the tumor position under-
goes random fluctuations in addition to the cyclic respi-
ratory motion. MC sampling addresses this by sampling
a greater portion of the tails of this distribution (rela-
tive to using the expectation value), thereby generating
a distribution of positions with a more realistic propor-
tion of large deviations. One may expect the MC method
to increase trajectory error; however, under certain con-
ditions one would expect a more complete sampling of
the error distribution to result in a more accurate calcu-
lation of derived metrics (such as target dosimetry). As
the trajectory noise increases, the Base and Phase meth-
ods to overestimate the true tumor dose, as the expecta-
tion value of the distribution likely lies within the PTV.
MC sampling slightly increases error in an absolute sense
(Fig. 4), but is a conservative estimate of D90/D95 target
dose metrics in noisy trajectories (Fig. 5). MC methods
may be useful for calculating dose to the prescription vol-
ume, and could constitute a worst-case scenario estimate
of tumor dose. However, for organs-at-risk and other
volumes, one would likely use expectation-based position
estimation (i.e. Base or Phase), which yields a more ac-
curate result.
V. CONCLUSIONS
We have developed methods for accurately determining
the trajectory of highly-mobile abdominal tumors using
cone-beam CT projections. These methods have been
applied to reconstruct the 3D trajectory of a respiratory
motion phantom, and to calculate the dose received un-
der that trajectory. Results were calculated without res-
piratory phase or Monte Carlo corrections (Base), with
phase corrections only (Phase), with Monte Carlo correc-
tions only (MC), and with both phase and Monte Carlo
corrections (PhaseMC). In all methods, errors in mean
position did not exceed 0.1 mm, and the RMS trajectory
error was only 3.8% of the total range of motion. Using
phase-resolved methods Phase and PhaseMC, the mean
dose and mean absolute dose were calculated with over
99% accuracy, and D90/D95 were determined to within
0.5% relative to the prescription dose. These methods
can be applied to estimate the dose-of-the-day for mobile
tumors, and can aid in the selection of motion manage-
ment strategies.
VI. ACKNOWLEDGEMENTS
The authors would like to thank Hirotatsu Armstrong
for several helpful discussions and comments regarding
this work.
10
REFERENCES
1. P. J. Keall, G. S. Mageras, J. M. Balter, R. S. Emery,
K. M. Forster, S. B. Jiang, J. M. Kapatoes, D. A. Low, M. J.
Murphy and B. R. Murray, ”The management of respiratory
motion in radiation oncology report of AAPM Task Group
76,” Medical Physics 33, 3874 (2006).
2. S. H. Benedict, K. M. Yenice, D. Followill, J. M. Galvin,
W. Hinson, B. Kavanagh, P. Keall, M. Lovelock, S. Meeks and
L. Papiez, ”Stereotactic body radiation therapy: the report
of AAPM Task Group 101,” Medical Physics 37, 4078 (2010).
3. D. A. Jaffray, J. H. Siewerdsen, J. W. Wong and A.
A. Martinez, ”Flat-panel cone-beam computed tomography
for image-guided radiation therapy,” Int J Rad Oncol* Biol*
Phys 53, 1337-1349 (2002).
4. T. Pan, T.-Y. Lee, E. Rietzel and G. T. Chen, ”4D-
CT imaging of a volume influenced by respiratory motion on
multi-slice CT,” Medical Physics 31, 333 (2004).
5. H. H. Liu, P. Balter, T. Tutt, B. Choi, J. Zhang, C.
Wang, M. Chi, D. Luo, T. Pan and S. Hunjan, ”Assessing
respiration-induced tumor motion and internal target volume
using four-dimensional computed tomography for radiother-
apy of lung cancer,” International Journal of Radiation On-
cology* Biology* Physics 68, 531-540 (2007).
6. C. R. Ramsey, D. Scaperoth, D. Arwood and A. L.
Oliver, ”Clinical efficacy of respiratory gated conformal radi-
ation therapy,” Medical Dosimetry 24, 115-119 (1999).
7. P. Kupelian, T. Willoughby, A. Mahadevan, T. Djemil,
G. Weinstein, S. Jani, C. Enke, T. Solberg, N. Flores and D.
Liu, ”Multi-institutional clinical experience with the Calypso
System in localization and continuous, real-time monitoring
of the prostate gland during external radiotherapy,” Interna-
tional Journal of Radiation Oncology* Biology* Physics 67,
1088-1098 (2007).
8. M. J. Murphy, ”Tracking moving organs in real time,”
Seminars in Radiation Oncology 14, 91-100 (2004).
9. P. J. Keall, H. Cattell, D. Pokhrel, S. Dieterich, K.
H. Wong, M. J. Murphy, S. S. Vedam, K. Wijesooriya and
R. Mohan, ”Geometric accuracy of a real-time target track-
ing system with dynamic multileaf collimator tracking sys-
tem,” International Journal of Radiation Oncology* Biology*
Physics 65, 1579-1584 (2006).
10. H. Shirato, K. Suzuki, G. C. Sharp, K. Fujita, R. On-
imaru, M. Fujino, N. Kato, Y. Osaka, R. Kinoshita and H.
Taguchi, ”Speed and amplitude of lung tumor motion pre-
cisely detected in four-dimensional setup and in real-time
tumor-tracking radiotherapy,” International Journal of Ra-
diation Oncology* Biology* Physics 64, 1229-1236 (2006).
11. Y. Seppenwoolde, H. Shirato, K. Kitamura, S. Shimizu,
M. van Herk, J. V. Lebesque and K. Miyasaka, ”Precise and
real-time measurement of 3D tumor motion in lung due to
breathing and heartbeat, measured during radiotherapy,” In-
ternational Journal of Radiation Oncology* Biology* Physics
53, 822-834 (2002).
12. B. Cho, P. R. Poulsen, A. Sloutsky, A. Sawant and P.
J. Keall, ”First demonstration of combined kV/MV image-
guided real-time dynamic multileaf-collimator target track-
ing,” International Journal of Radiation Oncology* Biology*
Physics 74, 859-867 (2009).
13. K. Malinowski, T. J. McAvoy, R. George, S. Diet-
rich and W. D. DSouza, ”Incidence of changes in respiration-
induced tumor motion and its relationship with respiratory
surrogates during individual treatment fractions,” Interna-
tional Journal of Radiation Oncology* Biology* Physics 82,
1665-1673 (2012).
14. A. P. Shah, P. A. Kupelian, B. J. Waghorn, T. R.
Willoughby, J. M. Rineer, R. R. Maon, M. A. Vollenweider
and S. L. Meeks, ”Real-Time Tumor Tracking in the Lung Us-
ing an Electromagnetic Tracking System,” International Jour-
nal of Radiation Oncology* Biology* Physics (2013).
15. J. Yun, K. Wachowicz, M. Mackenzie, S. Rathee, D.
Robinson and B. Fallone, ”First demonstration of intrafrac-
tional tumor-tracked irradiation using 2D phantom MR im-
ages on a prototype linac-MR,” Medical Physics 40, 051718
(2013).
16. W. G. Park, B. M. Yan, D. Schellenberg, J. Kim, D. T.
Chang, A. Koong, C. Patalano and J. Van Dam, ”EUS-guided
gold fiducial insertion for image-guided radiation therapy of
pancreatic cancer: 50 successful cases without fluoroscopy,”
Gastrointestinal endoscopy 71, 513-518 (2010).
17. W. Wunderink, A. Mndez Romero, W. De Kruijf, H. De
Boer, P. Levendag and B. Heijmen, ”Reduction of respiratory
liver tumor motion by abdominal compression in stereotactic
body frame, analyzed by tracking fiducial markers implanted
in liver,” International Journal of Radiation Oncology* Biol-
ogy* Physics 71, 907-915 (2008).
18. M. Imura, K. Yamazaki, H. Shirato, R. Onimaru, M.
Fujino, S. Shimizu, T. Harada, S. Ogura, H. Dosaka-Akita
and K. Miyasaka, ”Insertion and fixation of fiducial markers
for setup and tracking of lung tumors in radiotherapy,” In-
ternational Journal of Radiation Oncology* Biology* Physics
63, 1442-1447 (2005).
19. C. Wu, R. Jeraj, G. H. Olivera and T. R. Mackie, ”Re-
optimization in adaptive radiotherapy,” Physics in Medicine
and Biology 47, 3181 (2002).
20. G. D. Hugo, D. Yan and J. Liang, ”Population and
patient-specific target margins for 4D adaptive radiotherapy
to account for intra-and inter-fraction variation in lung tu-
mour position,” Physics in Medicine and Biology 52, 257
(2007).
21. C. Ozhasoglu and M. J. Murphy, ”Issues in respira-
tory motion compensation during external-beam radiother-
apy,” International Journal of Radiation Oncology* Biology*
Physics 52, 1389-1399 (2002).
22. P. R. Poulsen, B. Cho and P. J. Keall, ”Real-time
prostate trajectory estimation with a single imager in arc ra-
diotherapy: A simulation study,” Physics in medicine and
biology 54, 4019 (2009).
23. P. R. Poulsen, B. Cho, K. Langen, P. Kupelian and
P. J. Keall, ”Three-dimensional prostate position estimation
with a single x-ray imager utilizing the spatial probability
density,” Physics in medicine and biology 53, 4331 (2008).
24. R. Li, B. P. Fahimian and L. Xing, ”A Bayesian ap-
proach to real-time 3D tumor localization via monoscopic x-
ray imaging during treatment delivery,” Medical physics 38,
4205 (2011).
25. L. Papiez and M. Langer, ”On probabilistically de-
fined margins in radiation therapy,” Physics in Medicine and
Biology 51, 3921 (2006).
26. L. A. Feldkamp, L. C. Davis and J. W. Kress, ”Practical
cone-beam algorithm,” J Opt Sci Am A 1, 612-619 (1984).
27. J. C. Lagarias, J. A. Reeds, M. H. Wright and P. E.
Wright, ”Convergence properties of the Nelder–Mead simplex
method in low dimensions,” SIAM Journal on optimization 9,
112-147 (1998).
28. J. Lewis, ”Fast template matching,” Vision interface
95, 15-19 (1995).
11
29. J. Lewis, ”Fast normalized cross-correlation,” Vision
interface 10, 120-123 (1995).
30. D. R. Simpson, J. D. Lawson, S. K. Nath, B. S. Rose,
A. J. Mundt and L. K. Mell, ”A survey of imageguided radia-
tion therapy use in the United States,” Cancer 116, 3953-3960
(2010).
31. A. Richter, J. Wilbert, K. Baier, M. Flentje and M.
Guckenberger, ”Feasibility study for markerless tracking of
lung tumors in stereotactic body radiotherapy,” International
Journal of Radiation Oncology* Biology* Physics 78, 618-627
(2010).
32. J. Rottmann, M. Aristophanous, A. Chen and R.
Berbeco, ”A multi-region algorithm for markerless beam’s-eye
view lung tumor tracking,” Physics in medicine and biology
55, 5585 (2010).
33. J. Ge, L. Santanam, C. Noel and P. J. Parikh, ”Plan-
ning 4-Dimensional Computed Tomography (4DCT) Cannot
Adequately Represent Daily Intrafractional Motion of Ab-
dominal Tumors,” Int J Rad Oncol* Biol* Phys (2012).
34. A. Y. Minn, D. Schellenberg, P. Maxim, Y. Suh, S.
McKenna, B. Cox, S. Dieterich, L. Xing, E. Graves and K.
A. Goodman, ”Pancreatic tumor motion on a single planning
4D-CT does not correlate with intrafraction tumor motion
during treatment,” American Journal of Clinical Oncology
32, 364 (2009).
35. H. Shirato, Y. Seppenwoolde, K. Kitamura, R. On-
imura and S. Shimizu, ”Intrafractional tumor motion: lung
and liver,” Seminars in radiation oncology 14, 10-18 (2004).
36. P. R. Poulsen, B. Cho and P. J. Keall, ”A method to es-
timate mean position, motion magnitude, motion correlation,
and trajectory of a tumor from cone-beam CT projections for
image-guided radiotherapy,” International Journal of Radia-
tion Oncology* Biology* Physics 72, 1587-1596 (2008).
